William Lawrance
About William Lawrance
William Lawrance is a Senior Scientist at Adaptimmune, where he has worked since 2017. He has a strong background in molecular biology and biochemistry, with experience in developing novel platforms for tumor-specific TCR identification.
Work at Adaptimmune
William Lawrance has been serving as a Senior Scientist at Adaptimmune since 2017. In this role, he has contributed to the development of innovative therapies, particularly focusing on T-cell receptor (TCR) engineering. He previously worked at Adaptimmune as a Scientist from 2014 to 2016, where he gained foundational experience in the field. His current work includes leading the engineering of a TCR that is under investigation in the SPEARHEAD-1 clinical trial, which targets patients with Synovial Sarcoma or MRCLS.
Education and Expertise
William Lawrance holds a Bachelor of Science (BSc) in Biochemistry from the University of Warwick, where he studied from 2005 to 2009. He furthered his education at the University of Oxford, obtaining a Doctor of Philosophy (Ph.D.) in Clinical Medicine from 2009 to 2014. His expertise encompasses molecular biology, protein biochemistry, and cell biology, with proficiency in techniques such as flow cytometry, confocal microscopy, FPLC, and SPR. He has developed a novel platform for identifying naturally-occurring, tumour-specific TCRs.
Background
Before his tenure at Adaptimmune, William Lawrance was involved in various roles that contributed to his scientific foundation. He worked as a DPhil Student at the University of Oxford from 2009 to 2014, focusing on clinical medicine. He also held a position as a Biomedical Scientist at the same institution for four months in 2014. Earlier in his career, he served as an Assistant Analytical Chemist at Cefas for eight months in 2008-2009, which provided him with analytical skills relevant to his later work.
Achievements
William Lawrance authored a first-author publication detailing the regulation of LYVE-1, a protein significant in immune cell trafficking. His contributions to the field include developing a novel platform for TCR identification and leading engineering efforts for a TCR currently being investigated in a Phase 2/3 clinical trial. His work reflects a commitment to advancing scientific methods and exploring new opportunities within frontier science.